|
|
Article: VaxGen Begins Clinical Development of its Attenuated Smallpox Vaccine Candidate.
- Article from:
- PR Newswire
- Article date:
- October 20, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
VaxGen, Inc. (VXGN.PK) announced today that it has initiated a Phase I/II clinical trial to evaluate the safety and immune response of its attenuated smallpox vaccine candidate, LC16m8. One of four clinical sites participating in this trial, University of Kentucky School of Medicine, will begin vaccinating volunteers today in the first clinical study of LC16m8 in the United States. Sponsored by VaxGen, the trial is expected to enroll approximately 150 people.
(LOGO: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )
Saint Louis University Health Sciences Center, Stanford University and Vanderbilt University Medical Center are expected to begin ...